Pfizer
Pfizer Reports Q2 US Sales Growth for Ibrance Despite Declines in Other Markets, Greater Competition
Premium
Pfizer executives said the drug saw US sales growth for the first time since Q4 2020, despite more patients continuing to access the drug through its assistance program.
Princess Margaret Cancer Center is using recent grant funds to pilot a program where a nurse will help patients navigate biomarker profiling and clinical trial options.Â
Kisqali Shines as Novartis Posts Slight Decline in Q2 Revenues
The Swiss drugmaker's overall revenue fell 1 percent in Q2, but sales for the CDK4/6 inhibitor climbed 37 percent thanks to an overall survival advantage versus competitors.
Pfizer's Xalkori Gets FDA Approval for ALK-Positive Inflammatory Myofibroblastic Tumors
The agency approved the drug to treat both adult and pediatric patients with unresectable, recurrent, or refractory ALK-positive inflammatory myofibroblastic tumors.
Seven years of follow-up data showed that Ibrance plus letrozole didn't significantly improve survival compared to letrozole alone in advanced ER-positive breast cancer.